![]() This is the first study to demonstrate slightly better outcome in males and negative influence of diabetes on outcome in mCRC treated with BZ. Abdominal pain (RR 1.76, 95% CI, 1.1-2.8), accompanying diabetes (RR 1.76, 95% CI, 1.09-2.85), and unexplained weight loss (RR 2.73, 95% CI, 1.73-4.29) were associated with poor OS.īetter OS among mCRC patients with resectable primary and metastatic tumors was seen. Cox regression analysis suggested male sex (RR 0.65, 95% CI, 0.43-0.98), hematochezia (RR 0.63, 95% CI, 0.4-0.98), resectable primary tumor (RR 0.42, 95% CI, 0.24-0.72) and resectable metastatic mass (RR 0.32, 95% CI, 0.14-0.74) were found to be associated with longer OS. ![]() There was a slightly better OS among early responders compared to non-responders (median 21.5 months days versus 16.8 months, P = 0.07). On initial radiological evaluation following BZ therapy, 56 patients (m = 31, f = 25) had complete or partial response categorized as "early responders." Remaining patients (m = 46, f = 47) who were either stable or showed progressive disease were categorized as "non-responders." Fifty percent among early responders and 60% among non-responders demonstrated disease progression on follow up. Ascension has doctors across more than 12 states, ready to provide personalized, compassionate care near you. Find address location and contact information for this primary care clinic. Please try again with a different keyword or location. ![]() is a General Practice Clinic in Stevens Point, Wisconsin. Home View All Jobs (6,336) Results, order, filter 0 Jobs in Stevens Point, WI There are no jobs that match: Stevens Point, WI. Our study population had a mean age at diagnosis of 63.5 years (SD = 11) with median follow-up period of 19.4 months. Aspirus Stevens Point Hospital & Clinics, Inc. ![]() We reviewed retrospective medical records of all consecutive mCRC patients treated with BZ with or without CC at tertiary care center between 20 out of which149 patients (m = 77, f = 72) were eligible. Overall survival (OS) and/or progression free survival in mCRC patients receiving BZ with or without 5FU-based CC is thought to be affected by clinical and morphological factor(s). Bevacizumab (BZ) combined with first line chemotherapy (CC) has shown good clinical outcomes in metastatic colorectal cancer (mCRC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |